ライフサイエンスコーパス: prostatic acid phosphatase

1 f-assembling peptide fragment of the protein prostatic acid phosphatase.

2 esigned to stimulate T-cell immunity against prostatic acid phosphatase.

3 cell products, such as androgen receptor and prostatic acid phosphatase.

4 to that observed in the structural homologue prostatic acid phosphatase.

5 he yeast phosphoglycerate mutase and the rat prostatic acid phosphatase.

6 -nucleotidase, NT5E, and to a lesser extent, prostatic acid phosphatase.

7 They express prostatic acid phosphatase and androgen receptors and re

8 mation seen in the distantly related enzymes prostatic acid phosphatase and fructose-2,6-bisphosphata

9 y increased expression of tartrate-sensitive prostatic acid phosphatase as a broadly acting ectonucle

10 re cocultured ex vivo with recombinant mouse prostatic acid phosphatase as the target neoantigen.

11 argets such as prostate-specific antigen and prostatic acid phosphatase as well as, more recently, an

12 graphic studies compiled on the tartrate-rat prostatic acid phosphatase binary complex erroneously po

13 rhK4 also completely degraded prostatic acid phosphatase but failed to cleave serum al

14 In semen, proteolytic peptide fragments from prostatic acid phosphatase can form amyloid fibrils term

15 52(Shc) tyrophosphorylation was decreased in prostatic acid phosphatase cDNA-transfected stable subcl

16 s a two-domain fold similar to that of human prostatic acid phosphatase, consisting of an alpha/beta

17 on of fast-growing cells by cellular form of prostatic acid phosphatase (cPAcP) expression, a negativ

18 Cellular prostatic acid phosphatase (cPAcP), an authentic tyrosin

19 Human prostatic acid phosphatase crystals soaked in N-propyl-L

20 ty of protein tyrosine phosphatase, cellular prostatic acid phosphatase, decreased correspondingly in

21 FtHAP and human prostatic acid phosphatase differ in the orientation of

22 rtrate, which does not significantly inhibit prostatic acid phosphatase, does not form strong hydroge

23 t with autologous dendritic cells expressing prostatic acid phosphatase (for prostate cancer) or with

24 r of virus infection (SEVI) originating from prostatic acid phosphatase greatly increase XMRV infecti

25 artrate-refractory, which is reported as the prostatic acid phosphatase level.

26 The structure of human prostatic acid phosphatase, noncovalently bound in N-pro

27 state-specific androgen-responsive antigens, prostatic acid phosphatase (PAcP) and prostate-specific

28 The cellular form of human prostatic acid phosphatase (PAcP) is a neutral protein-t

29 Human prostatic acid phosphatase (PAcP) is a prostate epitheli

30 Human prostatic acid phosphatase (PAcP) is a prostate epitheli

31 Human prostatic acid phosphatase (PAcP) is a prostate epitheli

32 ast partly regulated by the cellular form of prostatic acid phosphatase (PAcP), a prostate-unique pro

33 el of ErbB-2, which is regulated by cellular prostatic acid phosphatase (PAcP), a protein tyrosine ph

34 tients immunized with a DNA vaccine encoding prostatic acid phosphatase (PAP) and a trans-vivo delaye

35 Prostatic acid phosphatase (PAP) and ecto-5'-nucleotidas

36 ing fragments of the abundant semen proteins prostatic acid phosphatase (PAP) and semenogelins form a

37 cs LSGraph and Ingenuity Systems) identified prostatic acid phosphatase (PAP) as an enzyme overexpres

38 The X-ray crystal structure of human prostatic acid phosphatase (PAP) in complex with a phosp

39 Prostatic acid phosphatase (PAP) is a prostate cancer-as

40 Prostatic acid phosphatase (PAP) is a prostate tumor ant

41 Prostatic acid phosphatase (PAP) is expressed in nocicep

42 Prostatic acid phosphatase (PAP) is just such an Ag that

43 Prostatic acid phosphatase (PAP) is uniquely expressed i

44 h a recombinant fusion protein consisting of prostatic acid phosphatase (PAP) linked to granulocyte-m

45 -free methodology is able to report on human prostatic acid phosphatase (PAP), a tumor marker, with a

46 is identical to the transmembrane isoform of prostatic acid phosphatase (PAP), an enzyme with unknown

47 tigens, prostate-specific antigen (PSA), and prostatic acid phosphatase (PAP), and is derived from th

48 on-induced pain may be mediated by decreased prostatic acid phosphatase (PAP), as PAP levels are mark

49 III study using Sipuleucel-T, an autologous prostatic acid phosphatase (PAP)-loaded dendritic cell i

50 sine by ecto-5'-nucleotidase (NT5E, CD73) or prostatic acid phosphatase (PAP, ACPP).

51 ted with KHT-1, while its mammalian homolog, prostatic acid phosphatase (PAP; also known as ACPP-201)

52 r peptide (a proteolytic cleavage product of prostatic acid phosphatase, PAP(248-286)).

53 ntigen, and vaccines such as those targeting prostatic acid phosphatase, prostate-specific antigen, a

54 ess a potent ectonucleotidase, transmembrane prostatic acid phosphatase (TMPAP), in the SSFP region.